ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including ALK-positive Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For ALK-positive Non-Small Cell Lung Cancer emerging drugs, the ALK-positive Non-Small Cell Lung Cancer pipeline analysis report provides a 360° view of the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The ALK-positive Non-Small Cell Lung Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the ALK-positive Non-Small Cell Lung Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, ALK-positive Non-Small Cell Lung Cancer clinical trials studies, ALK-positive Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, ALK-positive Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

 

  • Over 30+ ALK-positive Non-Small Cell Lung Cancer companies are evaluating 30+ ALK-positive Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the ALK-positive Non-Small Cell Lung Cancer market would significantly increase market revenue.

 

  • The leading ALK-positive Non-Small Cell Lung Cancer Companies includes GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.

 

  • Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies includes Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.

 

  • The ALK-positive Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence ALK-positive Non-Small Cell Lung Cancer R&D. The ALK-positive Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve ALK-positive Non-Small Cell Lung Cancer.

 

To explore more information on the latest breakthroughs in the ALK-positive Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook

 

ALK-positive Non-Small Cell Lung Cancer Overview

ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it’s a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.

 

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile

 

  • Ensartinib: Betta Pharmaceuticals/Xcovery

Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1/2 trial. A single-arm phase 2 trial of ensartinib as second-line treatment for patients with ALK-positive NSCLC previously treated with crizotinib has been completed in 156 Chinese patients, and a New Drug Application has been filed in China. An ensartinib global first-line phase 3 registration trial vs crizotinib is ongoing.

 

  • TQ-B3139 – Chia Tai Tianqing Pharmaceutical Group

TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.

 

For further information, refer to the detailed ALK-positive Non-Small Cell Lung Cancer Unmet Needs, ALK-positive Non-Small Cell Lung Cancer Market Drivers, and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here for ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.

 

ALK-positive Non-Small Cell Lung Cancer Pipeline Segmentation

 

Phases

  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Oral
  • Intramuscular
  • Intratumoral
  • Intravenous

 

Molecule Type

  • Gene therapies
  • Bispecific antibodies
  • Immunotherapies
  • Monoclonal antibodies
  • Small molecules

 

Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ ALK-positive Non-Small Cell Lung Cancer Treatment Landscape

 

Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

 

  • Coverage- Global

 

  • ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.

 

  • ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.

 

  • ALK-positive Non-Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for ALK-positive Non-Small Cell Lung Cancer Market Drivers and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here @ ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content 

  1. Introduction
  2. Executive Summary
  3. ALK-positive Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Ensartinib: Betta Pharmaceuticals/Xcovery
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
  14. Early Stage Products (Phase I)
  15. PLB1003: Beijing Pearl Biotechnology Limited Liability Company
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. ALK-positive Non-Small Cell Lung Cancer Key Companies
  21. ALK-positive Non-Small Cell Lung Cancer Key Products
  22. ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
  23. ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. ALK-positive Non-Small Cell Lung Cancer Analyst Views
  26. ALK-positive Non-Small Cell Lung Cancer Key Companies
  27. Appendix

 

Got Queries? Find out the related information on ALK-positive Non-Small Cell Lung Cancer Mergers and acquisitions, ALK-positive Non-Small Cell Lung Cancer Licensing Activities @ ALK-positive Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: